Compare BANL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANL | LSTA |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Misc Health and Biotechnology Services |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 20.9M |
| IPO Year | 2023 | N/A |
| Metric | BANL | LSTA |
|---|---|---|
| Price | $0.41 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 27.5K | 23.1K |
| Earning Date | 09-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $580,456,800.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.38 | N/A |
| 52 Week Low | $0.40 | $1.81 |
| 52 Week High | $1.30 | $4.20 |
| Indicator | BANL | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 35.09 |
| Support Level | $0.40 | $2.00 |
| Resistance Level | $0.46 | $2.17 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.41 | 3.23 |
CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.